Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (642)	8/5/1999 9:27:00 AM
From: Dr. John M. de Castro	Respond to of 1494

The wait for results will not be long. Merz now has their European Phase III data in hand (the US data will not be available till the end of the year). Merz will be releasing the data publicly in late September. This means that the data are available for potential partners to look over. The prior data were excellent. In addition, the recent run up in NTII stock value suggests to me that the new data are at least as good and contain better end points. Something is definitely up at NTII and all the pointers are suggesting that we may see movement on the partnership front in the next month or two. The fact that Merz and NTII waited for the results from the Phase III trials to come in means that, if the results are good, its gonna cost the pharmas. Interested pharmas will have to pay more for the marketing rights. After all their risk is markedly reduced after positive Phase III data. NTII/Merz should be getting far better royalties, up-front payments and milestone payments. What this in turn may mean is that the up-front payment and the milestones may well solve NTII's financial problems. In addition, the pharma will pay for the rest of the trials. So, NTII will incur little cost in further development. If things develop according to this scenario, NTII will be in great shape. Best regards John de C